Physician profile
Bernard D Geller
NPI 1427132968
$2,744.34
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $773 · 2021: $1,020 · 2022: $48.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $451.28 | 2019-2021 | |
| Csl Behring | $294.21 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $273.34 | 2019-2022 | |
| Optinose US, INC. | $204.62 | 2019-2021 | |
| Octapharma USA, INC. | $195.17 | 2020-2021 | |
| Genzyme Corporation | $187.37 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $163.07 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $129.33 | 2021 | |
| Pharming Healthcare, INC. | $126.01 | 2019-2020 | |
| Kaleo, INC. | $124.65 | 2019-2021 | |
| Genentech USA, INC. | $88.51 | 2019-2020 | |
| Glaxosmithkline, LLC. | $84.70 | 2019-2021 | |
| Shire North American Group INC | $62.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.19 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $49.43 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $42.36 | 2019-2021 | |
| Alk-Abello, INC | $38.24 | 2019 | |
| Paratek Pharmaceuticals, INC. | $30.49 | 2020 | |
| Biocryst Pharmaceuticals, INC. | $28.46 | 2020 | |
| Sanofi Pasteur INC. | $25.21 | 2019 | |
| Biocryst US Sales Co., LLC | $22.24 | 2021 | |
| Horizon Therapeutics Plc | $20.67 | 2019 | |
| Eyevance Pharmaceuticals LLC | $18.77 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.81 | 2019 | |
| Bio Products Laboratory USA, INC. | $16.78 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.